Efficacy and Safety Evaluation of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia or High Cardiovascular Risk Patients With Hypercholesterolemia on Lipid Modifying Therapy (ODYSSEY JAPAN)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 216 participants.

Also called NCT02107898

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 216 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02107898
Other papers using this trial's data
  • Efficacy and Safety of Alirocumab in Japanese Patients With Heterozygous Familial Hypercholesterolemia or at High Cardiovascular Risk With Hypercholesterolemia Not Adequately Controlled With Statins - ODYSSEY JAPAN Randomized Controlled Trial Circulation journal : official journal of the Japanese Circulation Society, 2016-08-25 DOI, PubMed 27452202 PubMed links an erratum for this paper. Erratum: PMID 27784878

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02107898. Randomized; quadruple masking; primary purpose treatment. Start 2014-03 (registry gives no type); primary completion 2015-01 (actual). Results posted on 2016-01-29.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety Evaluation of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia or High Cardiovascular Risk Patients With Hypercholesterolemia on Lipid Modifying Therapy (ODYSSEY JAPAN)
Condition
Hypercholesterolemia
Intervention (Drug)
Placebo (for alirocumab)
Intervention (Drug)
Alirocumab
Intervention (Drug)
Lipid-Modifying Therapy (LMT)
Lead sponsor
Sanofi (class: industry)
Collaborator
Regeneron Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct02107898
Content hash
01b62ee5d0027c14c3cc7e952a23390aa07480276b81c541ee777b3676ac6005